When Will The Music Stop?

When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves...

Next Up? INmune’s Big Week Finally Arrives

Frequently I hear from investors that something sounds, "too good to be true." And, being honest, more often than not, that's the case. But,...

Lantern Pharma Announces Pricing of $60 Million Public Offering

TW's Take: as usual, the biggest knock on this company was expectations of a financing. With this very large deal over, LTRN is now...

BOOM…Atomera Deal Highlights Another Bull Ride In The Market

Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...

Lantern Pharma Announces Launch of Antibody Drug Conjugate (ADC) Program to Target Solid Tumors...

TW's Take: we are very excited about this. ADC's are proving to be very effective and also companies focused on this space are in...

Put LP-184, a Potential Blockbuster in the Making, on Your Radar Screen

If you position yourself for success, sometimes you get lucky, right? It’s become common knowledge that A.I. is changing the way all companies do...

Lantern Pharma Announces Collaboration with World Leading Brain Cancer Program at Johns Hopkins to...

TW's Take: Hopkins is the world leader in GBM. This announcement means that there are now three leading research institutes working with LP-184 on...

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug...

Tailwinds' Take: LP-184 is proving to be a very valuable drug for fighting multiple types of cancer, especially as a co-therapy with the standard...

The Micro-Cap Rally Continues Full Force

November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...

Lantern Pharma Earnings Call Transcript

Panna Sharma: Thank you Marek, and good afternoon to everyone on the call today. Thank you for joining us for our third quarter 2020 conference...

Sell Mortimer, Sell!!!

What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...

Lantern Pharma Reports Third Quarter 2020 Financial Results & Continued Operational Progress

Tailwinds' Take: crossing a billion datapoints is a big goal achieved ahead of schedule. The platform being developed by Lantern is getting more powerful...

Lantern Pharma Advances Prostate Cancer Drug Development Research Collaboration with Georgetown University for LP-184,...

Tailwinds' Take: LP-184 has great potential as this collaboration with a leading research institute demonstrates. LTRN's unique AI capabilities have the potential to be...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

Wrapping Up A Chaotic Week

Markets were very volatile this past week, trading back and forth like a game of ping-pong. There's little doubt in my mind that the...

Lantern Pharma Announces Collaboration and Research Agreement with Fox Chase Cancer Center Focused on...

Tailwinds' Take: LTRN will benefit greatly from this partnership through development of LP-184 and gobs more data for their machine learning process. This quote...

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Illuminating Lantern Pharma

Today we are initiating coverage of Lantern Pharma (LTRN). Lantern is a clinical stage biopharmaceutical company that uses artificial intelligence, advanced machine learning, genomics,...

Lantern Pharma Announces Upcoming Conference Presentations

DALLAS, Aug. 27, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") platform to transform the...

Lantern Pharma Reports Second Quarter 2020 Financial Results and Continued Corporate Progress

DALLAS, July 30, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company using its proprietary RADR® artificial intelligence ("A.I.") platform to improve drug...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.